The Merck-Centocor comparisons

Investors hammered Centocor Inc. stock early last week, worried that Merck & Co.'s Aggrastat entry into the GPIIb/IIIa field would cut into sales of CNTO's ReoPro. However, a comparison of data from the two drugs showed they have little to fear, as ReoPro has produced stronger data with a more attractive dosing schedule.

CNTO, which lost $4.875 on the first three trading sessions, rebounded by Friday to close at $33.50, off $0.375 on the week on a total of 14.3 million shares traded.

Merck (Whitehouse Station, N.J.) presented positive data from two trials of Aggrastat at the Amerian College of Cardiology meeting in Anaheim, Calif. Merck's two trials and CNTO's CAPTURE trial (see BioCentury Sept.

Read the full 1131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE